Severe hyperlipidemia associated with drug-induced cholestatic liver disease - A case report

Sep 28, 2026

Uploaded by Bulrr

BACKGROUND: The incidence of hyperlipidemia continues to rise with changes in living standards and diet. Hyperlipidemia is linked to multiple diseases, and drug-induced cholestasis can cause elevated serum cholesterol and triglycerides, termed secondary hyperlipidemia, increasing cardiovascular risk. CASE SUMMARY: A 49-year-old woman is presented with refractory hyperlipidemia associated with cholestatic liver disease. CONCLUSION: Effective management requires individualized treatment and close monitoring of biochemical indices and clinical symptoms to ensure efficacy and prognosis.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages10

Reading Time25 min

AccessFree to download

Abstract

Background

Case Summary

Conclusion

Introduction

Core Tip

Citation

| W | J | H | World Journal of
Hepatology | | --- | --- | --- | --- | Submit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Hepatol 2025 December 27; 17(12): 111414 DOI: 10.4254/wjh.v17.i12.111414 ISSN 1948-5182 (online) CASE REPORT Severe hyperlipidemia associated with drug-induced cholestatic liver disease: A case report Meng-Jiao Xu, Xin Wei, Yao Lu, Lei Sun, Yao Xie, Ming-Hui Li Specialty type: Gastroenterology and hepatology Provenance and peer review: Unsolicited article; Externally peer reviewed. Peer-review model: Single blind Peer-review report’s classification Scientific Quality: Grade B, Grade C Novelty: Grade B, Grade C Creativity or Innovation: Grade A, Grade B Scientific Significance: Grade C, Grade C P-Reviewer: Alrez MN, PhD, Professor, Syria; Mburu SN, PhD, Academic Fellow, Senior Scientist, Kenya Received: July 3, 2025 Revised: August 11, 2025 Accepted: November 21, 2025 Published online: December 27, 2025 Processing time: 177 Days and 4.7 Hours Meng-Jiao Xu, Xin Wei, Yao Lu, Yao Xie, Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, Beijing 100015, China Lei Sun, Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, Beijing 100015, China Ming-Hui Li, Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing 100015, China Co-first authors: Meng-Jiao Xu and Xin Wei. Corresponding author: Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, [China.](China. wuhm2000@sina.com)[ wuhm2000@sina.com](China. wuhm2000@sina.com) Abstract BACKGROUND The global incidence of hyperlipidemia has been increasing on an annual basis, concomitant with improvements in living standards and dietary changes. Hyperlipidemia is closely associated with the development of numerous diseases, and in clinical cases, drug-induced cholestasis may lead to elevated serum cholesterol and triglyceride levels, a phenomenon known as secondary hyperlipidemia. Hyperlipidemia is recognized as a significant risk factor for the development of cardiovascular disease. Therefore, effective monitoring and control of lipid levels is crucial in the management of patients diagnosed with drug-induced cholestatic liver disease. CASE SUMMARY We present a special case of refractory hyperlipidemia associated with cholestatic liver disease in a 49-year-old woman. CONCLUSION In the treatment of clinical cases of drug-induced cholestatic liver disease and hyperlipidemia, it is essential for medical professionals to consider the patient’s overall condition, formulate an individualized treatment plan, and closely monitor the patient’s biochemical indices and clinical symptoms to ensure treatment efficacy and prognosis. WJH [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 27, 2025 Volume 17 Issue 12 Xu MJ et al. Drug-induced cholestatic liver disease-related hyperlipidemia Key Words: Drug-induced liver injury; Cholestasis; Hyperlipidemia; Glucocorticosteroid; Case report ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. Core Tip: Hyperlipidemia is closely associated with the development of multiple diseases and is widely recognized as a major risk factor for cardiovascular disease. In clinical settings, drug-induced cholestatic liver disease can increase blood cholesterol and triglyceride levels, a condition known as secondary hyperlipidemia. Furthermore, lipid overload can exacerbate hepatic oxidative stress. Therefore, accurate recognition and management of hyperlipidemia are crucial for systemic health and the functioning of multiple organ

FAQs

What condition is highlighted in this case report?

The report focuses on severe hyperlipidemia associated with drug-induced cholestatic liver disease.

What is the key clinical context described in the background?

It states that drug-induced cholestasis can elevate serum cholesterol and triglycerides, creating secondary hyperlipidemia and increasing cardiovascular risk.

How should clinicians manage patients with drug-induced cholestatic liver disease and hyperlipidemia?

The conclusion emphasizes individualized treatment based on the patient’s overall condition and close monitoring of biochemical indices and clinical symptoms.

Sep 28, 2026

Uploaded by Bulrr